NASDAQ · Key Statistics

Cartesian Therapeutics, Inc. (RNAC) P/E Ratio, ROE & Key Statistics

$6.12 NASDAQ: RNAC Market Cap $186.68M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Cartesian Therapeutics, Inc. (RNAC), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-1.29
P/B ratioShare price divided by book value per share.-1.48
P/S ratioMarket value divided by annual revenue.188.97
PEG ratioP/E divided by the earnings growth rate.0.01
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.-1.00
EV / RevenueEnterprise value against annual revenue.127.86
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-77.52%
Free cash flow yieldFree cash flow as a percentage of market value.-46.17%
Price / free cash flowMarket value divided by free cash flow.-2.17

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.100.00%
Operating marginRevenue left after operating costs.-2900.00%
Net marginRevenue left after every cost, including tax and interest.-4333.33%
Return on equityProfit as a percentage of shareholders’ equity.97.73%
Return on assetsProfit as a percentage of total assets.-44.01%
Return on capital employedOperating profit against the capital the business uses.-36.82%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.8.38
Quick ratioThe same, excluding inventory.8.38
Cash ratioCash alone against current liabilities.8.33
Debt to equityTotal borrowings against shareholders’ equity.-0.46
Debt to assetsTotal borrowings against total assets.0.04
Interest coverageHow many times operating profit covers the interest bill.-36.09

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$5.02
Book value per shareShareholders’ equity divided by shares outstanding.−$4.30
Market capitalisationShare price times shares outstanding.$186.68M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$130.69M

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Cartesian Therapeutics, Inc. (RNAC) statistics — frequently asked questions

What is Cartesian Therapeutics, Inc.'s P/E ratio?

Cartesian Therapeutics, Inc. (RNAC) trades on a price-to-earnings ratio of -1.29. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Cartesian Therapeutics, Inc.'s return on equity?

Cartesian Therapeutics, Inc. (RNAC) reports a return on equity of 97.73%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Cartesian Therapeutics, Inc. carry?

Cartesian Therapeutics, Inc. (RNAC) has a debt-to-equity ratio of -0.46, which compares total borrowings with shareholders' equity.

What is Cartesian Therapeutics, Inc.'s profit margin?

Cartesian Therapeutics, Inc. (RNAC) keeps -4333.33% of revenue as net profit after every cost, including tax and interest.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.